IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immatics N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$7.05+0.32 (+4.75%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -928.1% | – | |
| Return on assets | – | -108.7% | – | |
| Current ratio | – | 3.08 | 11.72 | |
| Interest coverage | – | -6.9× | -5.0× | |
| Diluted shares | – | 48M | 122M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Immatics generated €537.76M from operations and spent €64.47M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€537.76M
Used
€64.47M
Capital expenditure€64.47M100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 3 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-€176.63M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-€176.63M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.26 → 11.72
- No dilutionShare count did not rise107M → 122M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –